How to Take Adagrasib Correctly?

How to Take Adagrasib Correctly?

Standard Dosage:

The recommended dosage is 600 mg (three 200 mg tablets) taken twice daily, approximately every 12 hours, at the same times each day. You may take it with or without food.

Administration:

Swallow the tablets whole. Do not chew, crush, or split the tablets. Do not take any tablets that are broken or damaged.

Combination Therapy:

If you are taking this medication for colorectal cancer, your doctor will also administer cetuximab via intravenous infusion, typically once weekly or every two weeks.

Treatment Adjustments:

If you experience severe side effects, your doctor may temporarily interrupt treatment, reduce the dose, or permanently discontinue the medication. Follow your doctor's instructions carefully and do not make any changes on your own.

What to Do If You Miss a Dose or Vomit After Taking Adagrasib?

If You Miss a Dose:

If it has been less than 4 hours since the scheduled dose, take the missed dose immediately. If it has been more than 4 hours, skip the missed dose and take the next dose at your regularly scheduled time. Do not take two doses at once to make up for a missed dose.

If You Vomit After Taking a Dose:

Do not take an extra dose. Wait and take your next dose as originally scheduled. Setting a timer or calendar reminder can help you take your medication regularly.

Overdose:

If you suspect you have taken too much medication, contact your healthcare provider immediately, call the Poison Help line at 1-800-222-1222, or go to the nearest hospital emergency room.

How Effective Is Adagrasib?

For Non-Small Cell Lung Cancer (NSCLC):

In a clinical trial of 116 evaluable patients with KRAS G12C-mutant advanced NSCLC, 43% (48 patients) experienced significant tumor shrinkage or complete disappearance after treatment with Adagrasib monotherapy. Among them, 47 had tumor shrinkage and 1 had all signs of cancer disappear. The median duration of tumor response was 8.5 months, with some patients responding for more than 1 year. A key advantage of Adagrasib is that it does not require treatment interruption; you can start taking it immediately after completing first-line therapy.

For Colorectal Cancer (CRC):

In a trial combining Adagrasib with cetuximab, 34% (32 out of 94 evaluable patients) with KRAS G12C-mutant advanced CRC who had previously received multiple chemotherapies experienced tumor shrinkage. The median duration of tumor response was 5.8 months. Although no patient achieved complete tumor disappearance, this targeted combination offers a new chemotherapy-free treatment option for patients who no longer respond to conventional chemotherapy.